| 5.3243 -0.356 (-6.26%) | 09-09 12:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.89 | 1-year : | 8.04 |
| Resists | First : | 5.9 | Second : | 6.89 |
| Pivot price | 5.52  |
|||
| Supports | First : | 5.14 |
Second : | 4.67 |
| MAs | MA(5) : | 5.66 |
MA(20) : | 5.42 |
| MA(100) : | 4.92 |
MA(250) : | 4.32 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 57.4 |
D(3) : | 79.8 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 6.44 | Low : | 2.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AVIR ] has closed above bottom band by 17.5%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.85 - 5.88 | 5.88 - 5.9 |
| Low: | 5.57 - 5.6 | 5.6 - 5.63 |
| Close: | 5.62 - 5.68 | 5.68 - 5.72 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Tue, 08 Sep 2026
Atea CEO to speak at a New York healthcare conference Sept. 15 - Stock Titan
Wed, 12 Aug 2026
Atea Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-08-12 - Seeking Alpha
Sat, 25 Jul 2026
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
Thu, 25 Jun 2026
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 18 Jun 2026
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 80 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 13.3 (%) |
| Held by Institutions | 79 (%) |
| Shares Short | 7,670 (K) |
| Shares Short P.Month | 7,760 (K) |
| EPS | -2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.8 % |
| Return on Equity (ttm) | -58.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.94 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -152 (M) |
| Levered Free Cash Flow | -93 (M) |
| PE Ratio | -2.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|